1.
Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D’Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A. Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica 2022;107(1):321-325; https://doi.org/10.3324/haematol.2021.278655.